ANI Pharmaceuticals, Inc. (ANIP) Stock Price & Analysis
ANI Pharmaceuticals, Inc. (ANIP) closed at USD 71.71 on Wednesday, October 28, 2026, up 0.76% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 71.17; the Oct 28, 2026 session ranged USD 70.32–72.76 on volume of 335,881 shares. Market capitalization is $1.65B, with a 52-week range of USD 69.58–95.57 (NGM). Source: Nexqual, retrieved October 29, 2026 at 10:35 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ANIP.md
Key facts (ANIP)
- Last four reported quarters (through Jun 30, 2026): revenue $978M, net income $108M (11.1% margin), free cash flow $173M (SEC filings).
- Valuation: P/E 15.2x (avg 37.4x at the last 2 fiscal year-ends), EV/EBITDA 6.7x, net cash $58.7M.
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 105.78 (range 85–121).
- Total return with dividends: 1Y -22.3% vs S&P 500 +13.6%; 5Y +91.8% vs S&P 500 +79.8%.
- Next earnings: 2026-11-05, EPS estimate USD 2.18, revenue estimate $280M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ANIP)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $216M | $316M | $487M | $614M | $883M | $978M |
| Operating income | -$39.8M | -$35.3M | $47.0M | $584K | $111M | $150M |
| Net income | -$42.6M | -$47.9M | $18.8M | -$18.5M | $78.3M | $108M |
| EPS (diluted) | -$3.40 | -$3.05 | $0.85 | -$1.04 | $3.32 | — |
| Free cash flow | $765K | -$40.1M | $110M | $47.8M | $171M | $173M |
| Operating margin | -18.4% | -11.2% | 9.6% | 0.1% | 12.6% | 15.4% |
| Net margin | -19.7% | -15.1% | 3.9% | -3.0% | 8.9% | 11.1% |
| Revenue growth | +3.7% | +46.4% | +53.9% | +26.2% | +43.8% | — |
| Cash + short-term investments | $100M | $48.2M | $221M | $145M | $286M | — |
| Total debt | $287M | $287M | $286M | $318M | $309M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ANIP)
P/E 15.2x · P/S 1.7x · EV/EBITDA 6.7x · EV/Sales 1.6x · P/FCF 9.5x · P/B 2.8x · FCF yield 10.50% · Earnings yield 6.58% · Dividend yield (paid, TTM) 0.02% · Buyback yield (TTM) 1.35% · Net cash $58.7M · EV $1.59B
P/E at fiscal year-ends: Dec 2025 21.4x, Dec 2023 53.4x.
Analysts (ANIP)
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 105.78 (low 85, high 121).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | Oppenheimer | Initiated | Perform | $85 |
| 2026-08-10 | Guggenheim | Target lowered | Buy | $124 → $119 |
| 2026-08-10 | Canaccord Genuity | Target lowered | Hold | $91 → $90 |
| 2026-07-17 | Canaccord Genuity | Initiated | Hold | $91 |
| 2026-07-10 | Guggenheim | Reiterated | Buy | $124 |
Total return (dividends reinvested) (ANIP)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -22.3% | +91.8% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | -22.3% | +13.9% |
| Volatility (annualized) | 31.4% | 41.5% |
| Max drawdown | -25.7% (Nov 2025→Oct 2026) | -52.1% (Dec 2021→Jun 2022) |
ANIP earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 7, 2026 | Quarter ended Jun 30, 2026 | $2.21 | $2.04 | Beat +8.3% | -8.3% |
| May 8, 2026 | Quarter ended Mar 31, 2026 | $2.05 | $1.30 | Beat +57.7% | -6.2% |
| Feb 27, 2026 | Quarter ended Dec 31, 2025 | $2.33 | $1.98 | Beat +17.7% | -2.5% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $2.33 | $1.98 | Beat +17.7% | +7.9% |
| Nov 10, 2025 | Quarter ended Sep 30, 2025 | $2.04 | $1.77 | Beat +15.3% | -2.1% |
| Nov 7, 2025 | Quarter ended Sep 30, 2025 | $2.04 | $1.77 | Beat +15.3% | -1.4% |
| Sep 8, 2025 | — | — | — | — | +3.3% |
| Aug 8, 2025 | — | — | — | — | +23.0% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
ANIP recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 24, 2026 | 8-K | Director or executive officer change, or pay arrangement “On August 19, 2026, the Board of Directors (the "Board") of ANI Pharmaceuticals, Inc. (the "Company") appointed Henry Gosebruch to serve on the Board as a director with a term expiring at the Company's 2027 annual meeting of stockholders. Mr. Gosebruch, 53, has served as Chief Executive Officer and a member of the board of directors of Lakefront Biotherapeutics NV, a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need,…” |
| Aug 7, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 7, 2026 | 8-K | Quarterly results; Regulation FD disclosure |
| Jul 27, 2026 | Schedule 13G/A | BlackRock, Inc.: 12.8% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
ANIP suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Alimera Sciences | “In addition, due to price referencing within the EEA, the UK and certain other countries, existing pricing in our current markets could be negatively affected by a change in pricing in a country where Alimera historically has reimbursement or by a new price in a country where we obtain reimbursement approval in the future.” |
| Partner | Company and EyePoint Pharmaceuticals | “Pursuant to an amended and restated license agreement (the "A&R Collaboration Agreement") with EyePoint, our ILUVIEN-related patent rights are only for diseases of the human eye in Europe, the Middle East and Africa, and for diseases of the human eye excluding uveitis in the rest of the world.” |
| Partner | CVS Health (CVS) | “We have contracts with several major distributors in the U.S., including Anda, Smith Drug Company, Morris Dickson, CVS Caremark, Accredo, OptumRx, CuraScript and several other partners.” |
| Partner | Premier | “We have contracts with group purchasing organizations in the U.S., including ClarusONE, Walgreens Boots Alliance Development Group, Red Oak Sourcing, Econdisc, Optisource, Rx Sourcing Strategies, The Premier Group, Topco, The Buyer's Consortium, Managed Health Care Associates Inc., Asembia, and Premier Inc., among others.” |
| Partner | Managed Health Care Associates | “We have contracts with group purchasing organizations in the U.S., including ClarusONE, Walgreens Boots Alliance Development Group, Red Oak Sourcing, Econdisc, Optisource, Rx Sourcing Strategies, The Premier Group, Topco, The Buyer's Consortium, Managed Health Care Associates Inc., Asembia, and Premier Inc., among others.” |
Quoted from the company's 10-K filed Feb 27, 2026.
Companies that name ANIP in their SEC reports
| Relationship to ANIP | Company | Filing | Sentence |
|---|---|---|---|
| partner | EyePoint, Inc. (EYPT) | 10-K Mar 5, 2026 | “the success of current and future license and collaboration agreements, including our agreements with ANI Pharmaceuticals, Inc. (ANI), Equinox Science, LLC (Equinox), and Ocumension Therapeutics (Ocumension);” |
ANIP analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.18 | $2.51 | -13.0% | $280.2M | 9 |
| Next quarter (ends Dec 2026) | $2.82 | $2.85 | -1.0% | $319.3M | 9 |
| Current fiscal year (ends Dec 2026) | $9.26 | $9.42 | -1.7% | $1.10B | 9 |
| Next fiscal year (ends Dec 2027) | $10.13 | $10.76 | -5.9% | $1.22B | 9 |
ANIP options: expected move
Options price a move of about ±9.7% (±$7.00) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±6.8% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 22 | 48.1% | ±9.7% |
| Dec 18, 2026 | 50 | 40.9% | ±12.2% |
| Jan 15, 2027 | 78 | 36.7% | ±13.6% |
| Apr 16, 2027 | 169 | 35.2% | ±18.9% |
30-day implied volatility 34.8% vs 29.3% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 10:35 UTC)
| Price | USD 71.71 |
|---|---|
| Change | ▲ 0.76% (up) |
| Previous Close | USD 71.17 |
| Open | USD 70.78 |
| Day Range | USD 70.32 – 72.76 |
| 52-Week Range | USD 69.58 – 95.57 |
| Volume | 335,881 shares |
| Market Cap | $1.65B |
| Exchange | NGM |
Technical Analysis (ANIP)
Nexqual's technical model rates ANIP "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 29, 2026 at 10:35 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 49.69 (neutral) |
| vs SMA50 | Below (USD 73.16) |
| MACD | -0.41 (negative) |
Analyst Ratings (ANIP)
Wall Street analysts rate ANIP "Buy" based on 9 analysts, with a mean price target of USD 105.78 (range USD 85–121), per Nexqual as of October 29, 2026 at 10:35 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 105.78 |
| High Target | USD 121 |
| Low Target | USD 85 |
| Buy / Hold / Sell | 7 / 2 / 0 |
Earnings (ANIP)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD 2.18 |
| Revenue Estimate | $280.20M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.21 vs est 2.04 ▲ beat |
| 2026-03-31 | USD 2.05 vs est 1.3 ▲ beat |
| 2025-12-31 | USD 2.33 vs est 1.98 ▲ beat |
| 2025-09-30 | USD 2.04 vs est 1.77 ▲ beat |
Source: Nexqual, October 29, 2026 at 10:35 UTC.
Financials & Fundamentals (ANIP)
| Total Revenue | $978.38M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +25.90% |
| Gross Margin | +60.40% |
| Operating Margin | +14.97% |
| Profit Margin | +11.07% |
| ROE | +20.46% |
| Debt / Equity | 1.05 |
| Current Ratio | 2.91 |
| Total Cash | $376.96M |
| Total Debt | $626.03M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $172.99M (17.7% of revenue) |
Source: Nexqual, October 29, 2026 at 10:35 UTC.
Financial Health Score (ANIP)
Nexqual rates ANI Pharmaceuticals, Inc.'s overall financial health "Strong" across five dimensions, as of October 29, 2026 at 10:35 UTC.
| Growth | Strong — Revenue +44% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 60%, operating 15% (last 12 months) |
| Balance Sheet | Mixed — $360M cash and investments vs $301M debt (Jun 2026, SEC), net cash |
| Cash Flow | Strong — FCF $173M (last 4 quarters to Jun 2026, SEC), 18% margin |
| Efficiency | Solid — ROE 18%, ROA 7.2% (last 4 quarters, SEC) |
Ownership (ANIP)
| Insider Ownership | +5.39% |
|---|---|
| Institutional Ownership | +107.01% |
| Shares Outstanding | 22.96M |
| Float | 19.67M |
| Short % of Float | +18.41% |
Source: Nexqual, October 29, 2026 at 10:35 UTC.
Leadership (ANIP)
ANI Pharmaceuticals, Inc. is led by Nikhil Lalwani, President, CEO & Director, per Nexqual as of October 29, 2026 at 10:35 UTC.
| President, CEO & Director | Nikhil Lalwani |
|---|---|
| Senior VP of Finance & CFO | Stephen P. Carey |
| Senior Vice President of Generics | Ori Gutwerg |
| Head of R & D and COO of New Jersey Operations | Muthusamy Shanmugam MS R.Ph. |
| Vice President of Investor Relations | Irina Rivkind Koffler |
Major Backers & Investors (ANIP)
Notable institutional backers of ANI Pharmaceuticals, Inc. include Soleus Capital Management, L.P., Tang Capital Management, LLC, American Century Companies Inc, according to Nexqual as of October 29, 2026 at 10:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 3.78% |
| Tang Capital Management, LLC | 3.08% |
| American Century Companies Inc | 2.5% |
| Arrowstreet Capital, Limited Partnership | 2.45% |
| Global Alpha Capital Management Ltd. | 2.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.89% |
| Vanguard Group | 3.65% |
| State Street | 3.62% |
| Dimensional Fund Advisors | 2.72% |
| Geode Capital | 2.34% |
Source: Nexqual, October 29, 2026 at 10:35 UTC.
From ANI Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration ("FDA") approved the Company's Supplemental New Drug Application ("sNDA") for Cortrophin Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis ("MS") and rheumatoid arthritis ("RA"), in addition to excess urinary protein due to nephrotic syndrome.
- Any change in one of our API suppliers generally is required to be approved by the FDA through a prior approval supplement ("PAS").
- From time to time, we have experienced temporary disruptions in the supply of certain of such imported API due to FDA inspections and customs delays.
- Our development and manufacturing capabilities enable us to manufacture pharmaceuticals that are differentiated and include high potency, modified release, combination, and hormonal products.
Partnerships
- In the wake of the executive orders and related executive initiatives, a number of pharmaceutical manufacturers have announced direct-to-consumer offerings with discounted prices and/or reached agreement with the federal government regarding pricing for drugs, including prices for Medicaid drugs and newly launched products.
Legal & Regulatory Risks (Item 1A, quoted)
- Our manufacturing facilities or those of our third-party manufacturers or suppliers may fail to meet regulatory requirements. Failure to meet cGMP requirements could increase production costs or impact supply of our products.
- Any failure to comply with the complex reporting and payment obligations under the Medicaid Drug Rebate Program and other government pricing and price reporting programs may result in penalties and sanctions, which may have a material adverse effect on our business, financial position, and operating results.
- Any significant adverse events or undesirable side effects caused by our products may impact regulatory approval or market acceptance, or result in significant negative consequences.
- Litigation or third-party claims of intellectual property infringement would require us to divert resources and may prevent or delay our commercialization of our current products or the development or regulatory approval of other product candidates.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 41.08 | ▲ 0.29% |
| BHC | Bausch Health Companies Inc. | USD 6.92 | ▲ 9.67% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.07 | ▼ 0.81% |
| RGC | Regencell Bioscience Holdings L | USD 7.27 | ▼ 2.55% |
| LQDA | Liquidia Corporation | USD 45.72 | ▲ 0.62% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.77 | ▲ 0.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 10:35 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt